Humacyte (HUMA) Scheduled to Post Earnings on Friday

Humacyte (NASDAQ:HUMA) is set to release its earnings data before the market opens on Friday, May 10th. Analysts expect Humacyte to post earnings of ($0.23) per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings data on Friday, March 22nd. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.01. During the same period in the prior year, the firm posted ($0.21) earnings per share. On average, analysts expect Humacyte to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Humacyte Price Performance

Shares of NASDAQ HUMA opened at $4.51 on Thursday. The stock has a market capitalization of $537.05 million, a price-to-earnings ratio of -4.21 and a beta of 1.27. The business has a 50-day moving average of $3.49 and a 200-day moving average of $3.12. The company has a debt-to-equity ratio of 1.20, a current ratio of 4.52 and a quick ratio of 4.52. Humacyte has a fifty-two week low of $1.96 and a fifty-two week high of $5.12.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on HUMA. Piper Sandler restated a “neutral” rating and issued a $4.00 price objective on shares of Humacyte in a report on Tuesday, March 26th. Cantor Fitzgerald reiterated an “overweight” rating and set a $7.00 price target on shares of Humacyte in a report on Monday, April 1st. Finally, Benchmark reiterated a “buy” rating and set a $15.00 price target on shares of Humacyte in a report on Monday, March 25th.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.